Patents Issued in March 5, 2020
  • METHODS OF USING A PHENOXYPROPYLAMINE COMPOUND TO TREAT PAIN
    Publication number: 20200069672
    Abstract: The present disclosure relates to methods of treating pain, fibromyalgia, neuropathy, chemotherapy-induced pain, promoting an antihyperalgesic effect, and reducing sensitivity to pain, in a subject in need of such treatment comprising the administration of a therapeutically effective amount of Compound I, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
    Type: Application
    Filed: September 4, 2019
    Publication date: March 5, 2020
    Inventors: Remy LUTHRINGER, Nadine NOEL, Jay SAOUD
  • COMBINATION THERAPY USING C-C CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORS
    Publication number: 20200069673
    Abstract: The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
    Type: Application
    Filed: August 28, 2019
    Publication date: March 5, 2020
    Inventors: Shijie LI, Venkat Reddy MALI, Rajinder SINGH, Ju YANG, Penglie ZHANG
  • TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF
    Publication number: 20200069674
    Abstract: Compounds of Formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof; processes and intermediates for preparation thereof, compositions thereof, and uses thereof; are provided. Pharmaceutical compositions comprising a compound of Formula I, or enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof; wherein the compound is a double and/or triple agent or ligand for CYP2D6, 5-HT2A, and/or 5HT2C receptors, and/or acetylcholinesterase are provided.
    Type: Application
    Filed: November 3, 2019
    Publication date: March 5, 2020
    Inventors: SREENIVASARAO VEPACHEDU, HANS J MOEBIUS, ANTON BESPALOV
  • PHARMACEUTICAL PREPARATIONS OF SEBACOYL DINALBUPHINE AND ACETAMINOPHEN AND METHODS FOR TREATING PAIN
    Publication number: 20200069675
    Abstract: The present invention relates to pharmaceutical compositions/combination/kit and methods for treating pain, which provide synergistic analgesic effects and less side effects.
    Type: Application
    Filed: September 3, 2018
    Publication date: March 5, 2020
    Applicant: International Education Foundation
    Inventors: Oliver Yoa-Pu HU, Yen-Lun CHEN
  • METHODS OF SAFELY TRANSITIONING A SUBJECT TO BUPRENORPHINE
    Publication number: 20200069676
    Abstract: The present invention relates to methods and compositions for treating pain in a subject and safely transitioning a subject from a full ?-opioid receptor agonist to a partial ?-opioid receptor agonist.
    Type: Application
    Filed: September 10, 2019
    Publication date: March 5, 2020
    Applicant: BioDelivery Sciences International, Inc.
    Inventors: Andrew Finn, Todd Kirby, Lynn R. Webster
  • MARKERS FOR PERSONALIZED CANCER TREATMENT WITH LSD1 INHIBITORS
    Publication number: 20200069677
    Abstract: Provided herein are methods of treating cancers characterized by a high expression of GFIIB, comprising administering a therapeutically effective amount of a KDMIA inhibitor.
    Type: Application
    Filed: December 8, 2017
    Publication date: March 5, 2020
    Applicants: Constellation Pharmaceuticals, Inc., Constellation Pharmaceuticals, Inc.
    Inventors: John McGrath, Patrick Trojer
  • PHARMACEUTICAL COMPOSITION OF ORAL SUSPENSION OF ANTI-NEOPLASTIC ALKYLATING AGENTS
    Publication number: 20200069678
    Abstract: The present invention provides pharmaceutical composition of antineoplastic alkylating agent in oral suspension dosage form. The oral suspension composition comprises of alkylating agent with other pharmaceutical excipients such as vehicle, preservative, antioxidant, suspending agent, surfactant, sweetener and flavouring agent. The present invention is an oral suspension having improved stability and palatability. The present invention also provides oral solution with flavor that has masked bitter taste of the drug. Further, the present invention also provides a process for preparation thereof.
    Type: Application
    Filed: March 12, 2018
    Publication date: March 5, 2020
    Inventors: Sandip MEHTA, Manish UMRETHIA, Henil PATEL, Jayanta Kumar MANDAL
  • NINTEDANIB FOR USE IN METHODS FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASES BY COADMINISTRATION WITH OLADATEROL
    Publication number: 20200069679
    Abstract: Nintedanib can be used in methods for the treatment of interstitial lung diseases by coadministration with olodaterol.
    Type: Application
    Filed: December 6, 2017
    Publication date: March 5, 2020
    Inventors: Stefan WOLLIN, Eva WEX, Franziska HERRMANN
  • OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE
    Publication number: 20200069680
    Abstract: The present invention provides a method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor.
    Type: Application
    Filed: December 8, 2017
    Publication date: March 5, 2020
    Inventors: John S. Kovach, Zhengping Zhuang, Sze Chun Winson Ho, Herui Wang, Rongze Lu
  • CANNABINOID RECEPTOR MODULATORS
    Publication number: 20200069681
    Abstract: Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;
    Type: Application
    Filed: June 17, 2019
    Publication date: March 5, 2020
    Inventors: Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
  • PARP-1 AND METHODS OF USE THEREOF
    Publication number: 20200069682
    Abstract: The invention is directed to roles for PARP-1 in disease.
    Type: Application
    Filed: September 9, 2019
    Publication date: March 5, 2020
    Inventors: Hamid Boulares, Mohamed Ghonim, Amir Al-Khami, Augusto Ochoa
  • NOVEL METHODS
    Publication number: 20200069683
    Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
    Type: Application
    Filed: August 30, 2019
    Publication date: March 5, 2020
    Inventors: Peng LI, Robert DAVIS
  • THERAPEUTIC AGENT FOR TUMORS IDENTIFIED BY PHOSPHORYLATION OF PROTO-ONCOGENE PROTEIN BELONGING TO VAV FAMILY
    Publication number: 20200069684
    Abstract: The present invention provides a therapeutic agent and others for various tumors including angioimmunoblastic T-cell lymphoma (AITL), which is an orphan disease. The present invention relates to a therapeutic agent and others for tumors identified by phosphorylation of a proto-oncogene protein belonging to the VAV family, which comprises dasatinib or a prodrug thereof or a pharmacologically acceptable salt thereof or a hydrate or solvate thereof as an active ingredient.
    Type: Application
    Filed: April 24, 2019
    Publication date: March 5, 2020
    Applicant: University of Tsukuba
    Inventors: Shigeru CHIBA, Mamiko YANAGIMOTO
  • Dosing schedule for a combination of Ceritinib and an anti-PD-1 antibody molecule
    Publication number: 20200069685
    Abstract: The present disclosure relates to the field of pharmacy, particularly to ceritinib and a PD-1 inhibitor for use in the treatment of cancer. Specifically, the disclosure relates to a pharmaceutical combination comprising ceritinib, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, to a method for the treatment of cancer that involves administering the combination and to the use of the combination for the manufacture of a medicament for the treatment of cancer.
    Type: Application
    Filed: February 26, 2018
    Publication date: March 5, 2020
    Inventor: Jeffrey SCOTT
  • N-SUBSTITUTED INDOLE DERIVATIVES
    Publication number: 20200069686
    Abstract: The present invention relates to derivatives of formula (I) wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.
    Type: Application
    Filed: May 17, 2018
    Publication date: March 5, 2020
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN
  • Inhibitors of Multidrug Resistance Transporter P-Glycoprotein
    Publication number: 20200069687
    Abstract: The present disclosure provides a method of treating a subject that is resistant to one or more drugs by identifying a subject having one or more drug resistant cells; administering to the subject a pharmaceutically effective amount of an inhibitor compound, and contacting one or more drug resistant cells with the inhibitor compound to reduce the export of the inhibitor compound from the one or more drug resistant tumor cells and to block the transport of drug(s) from the one or more drug resistant cells.
    Type: Application
    Filed: November 6, 2019
    Publication date: March 5, 2020
    Inventors: John G. Wise, Pia D. Vogel, Frances K. Brewer, Courtney A. Follit, Amila K. Nanyakkara, Alexander R. Lippert, Maha Ali Aljowni
  • METHODS FOR THE TREATMENT OF CANCER
    Publication number: 20200069688
    Abstract: Disclosed herein are methods of treating cancer in a subject, wherein the subject is known to possess at least one genetic alteration in RET, comprising administering to the subject a therapeutically effective amount of N-[3-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N?-[5-(2,2,2-trifluoro-1, 1-dimethylethyl)-3-isoxazolyl]-urea, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 29, 2017
    Publication date: March 5, 2020
    Applicant: IGNYTA, INC.
    Inventors: Jonathan Ee-Ren Lim, Pratik S. Multani, Richard Landin, Rupal A. Patel, Jennifer Wright Oliver
  • QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
    Publication number: 20200069689
    Abstract: Compounds that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: May 3, 2018
    Publication date: March 5, 2020
    Inventors: Manmohan Reddy LELETI, Dillon Harding MILES, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF, Rhiannon THOMAS-TRAN
  • ARYLQUINAZOLINES
    Publication number: 20200069690
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: June 26, 2019
    Publication date: March 5, 2020
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS
    Publication number: 20200069691
    Abstract: The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.
    Type: Application
    Filed: December 19, 2017
    Publication date: March 5, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brian McKittrick, John P. Caldwell, John McCauley, Henry Vaccaro, Tin-Yau Chan, Hyunjin Kim, Elizabeth Smith, Liwu Hong, Tanweer Khan, Shihong Ying, Hongwu Wang, Peter D. Williams, Jae-Hun Kim, M. Brad Nolt, Maryann Caplen
  • BOVINE SUPPLEMENT FOR NEONATAL CALVES
    Publication number: 20200069692
    Abstract: The present invention relates generally to a feed supplement preparation for administration to ruminant animals and, more particularly, to a formulation for an oral bovine supplement for neonatal calves that delivers naturally occurring caffeine, antioxidants and other electrolytes in a stable liquid form of moderate viscosity.
    Type: Application
    Filed: August 30, 2018
    Publication date: March 5, 2020
    Inventors: Nathan C. Upah, Aaron N. Fritchen, Dennis M. McKilligan, Bradley W. Kolstad
  • DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION
    Publication number: 20200069693
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Application
    Filed: November 7, 2019
    Publication date: March 5, 2020
    Inventors: Thomas FRIEDL, Michael BRAUN, Kenji EGUSA, Hikaru FUJITA, Megumi MARUYAMA, Takaaki NISHIOKA
  • METHODS OF TREATING METASTATIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1
    Publication number: 20200069694
    Abstract: Methods of treating patients having metastatic or unresectable locally advanced HER2 positive cancer, e.g., breast cancer, with the antibody-drug conjugate trastuzumab-MCC-DM1 are provided, wherein the patients have received extensive prior treatment, e.g., with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab.
    Type: Application
    Filed: November 1, 2019
    Publication date: March 5, 2020
    Applicant: GENENTECH, INC.
    Inventors: Samuel Agresta, Barbara Klencke
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20200069695
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Inventors: James Aaron Balog, Steven P. Seitz, Susheel Jethanand Nara, Saumya Roy, Srinivasan Thangathirupathy, Soodamani Thangavel, Srinivas Cheruku
  • OPHTHALMIC INJECTABLE FORMULATION PREPARING AND OCULOPATHY TREATING AND PREVENTING
    Publication number: 20200069696
    Abstract: Disclosed are an ophthalmic injectable sustained-release formulation, a process for preparing the same and a method for treating and preventing oculopathy with the same. The ophthalmic injectable sustained-release formulation comprises a delivery system and a pharmaceutically acceptable excipient, wherein the delivery system is selected from the group consisting of microspheres, microcapsules, microparticles, liposomes, multivesicular liposomes, nanocrystals and nanoparticles.
    Type: Application
    Filed: August 28, 2019
    Publication date: March 5, 2020
    Inventor: Yunxiang LIU
  • TREATMENT OF CANCER AND INHIBITION OF METASTASIS
    Publication number: 20200069697
    Abstract: Compounds and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part.
    Type: Application
    Filed: February 12, 2018
    Publication date: March 5, 2020
    Applicant: Celex GmbH
    Inventors: Carsten Faltum, Leif Helth Jensen, Mustafa Djamgoz
  • TEXAPHYRIN-PT(IV) CONJUGATES AND COMPOSITIONS FOR USE IN OVERCOMING PLATINUM RESISTANCE
    Publication number: 20200069698
    Abstract: The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.
    Type: Application
    Filed: September 6, 2019
    Publication date: March 5, 2020
    Inventors: Jonathan L. SESSLER, Jonathan ARAMBULA, Zahid H. SIDDIK, Gregory THIABAUD
  • COMPOSITIONS AND METHODS FOR REDUCING BODY FAT
    Publication number: 20200069699
    Abstract: The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.
    Type: Application
    Filed: April 11, 2019
    Publication date: March 5, 2020
    Applicant: Topokine Therapeutics, Inc.
    Inventors: Cynthia L. Grosskreutz, Louis R. Pasquale, Michael S. Singer, Murat V. Kalayoglu
  • VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS
    Publication number: 20200069700
    Abstract: Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).
    Type: Application
    Filed: November 8, 2019
    Publication date: March 5, 2020
    Applicant: TherapeuticsMD, Inc.
    Inventors: Brian A. BERNICK, Julia M. AMADIO, Sebastian MIRKIN
  • HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS
    Publication number: 20200069701
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
    Type: Application
    Filed: November 8, 2019
    Publication date: March 5, 2020
    Applicant: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
  • ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING AN UNMICRONIZED SELECTIVE PROGESTERONE RECEPTOR AS ACTIVE AGENT
    Publication number: 20200069702
    Abstract: The subject matter of the present invention is pertinent to the field of oral delivery of pharmaceutically active agents. Embodiments of the instant invention disclose a liquid or semi-solid non-aqueous oral pharmaceutical fill composition comprising (a) a pharmaceutically effective amount of an unmicronized selective progesterone receptor modulator (SPRM) and (b) a polyethylene glycol (PEG) as well as methods for treating a variety of progesterone related disorders by orally administering such a composition.
    Type: Application
    Filed: December 7, 2017
    Publication date: March 5, 2020
    Inventor: Joseph S. Podolski
  • CHEMICAL ENTITIES THAT KILL SENESCENT CELLS FOR USE IN TREATING AGE-RELATED DISEASE
    Publication number: 20200069703
    Abstract: Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.
    Type: Application
    Filed: September 20, 2019
    Publication date: March 5, 2020
    Inventor: Nathaniel David
  • Methods Of Treating Prostate Cancer
    Publication number: 20200069704
    Abstract: Disclosed are methods of treating prostate cancer by administering abiraterone acetate plus prednisone with androgen deprivation therapy.
    Type: Application
    Filed: November 5, 2019
    Publication date: March 5, 2020
    Inventor: Namphuong Tran
  • NOVEL PARASITE THERAPY
    Publication number: 20200069705
    Abstract: There is disclosed herein a composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations: at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate.
    Type: Application
    Filed: September 9, 2019
    Publication date: March 5, 2020
    Inventor: Thomas Julius Borody
  • PRODRUGS OF 2-PMPA FOR HEALTHY TISSUE PROTECTION DURING PSMA-TARGETED CANCER IMAGING OR RADIOTHERAPY
    Publication number: 20200069706
    Abstract: The use of a class of prodrugs of 2-PMPA that alter tissue distribution of 2-PMPA to non-prostate tissues is disclosed. The presently disclosed prodrugs preferentially distribute to healthy tissues including the kidney, lacrimal glands, and salivary glands, which represent sites of off-target binding and toxicity for PSMA-targeted prostate cancer imaging agents and therapies. Accordingly, the 2-PMPA prodrugs can be used to pretreat, bind to, and shield the kidney and salivary glands from PSMA-targeted cytotoxic or radiotherapy.
    Type: Application
    Filed: April 11, 2018
    Publication date: March 5, 2020
    Inventors: Barbara Slusher, Michael Nedelcovych, Rana Rais, Clemens Kratochwil
  • COMPOSITIONS AND PRODUCTS FOR USE IN THE TREATMENT OF BONE FRACTURES AND DEFECTS
    Publication number: 20200069707
    Abstract: The invention relates to methods for treatment of bone fractures and defects, in particular to method that accelerate fracture healing, and to compositions, injectable in situ depot forming formulations and patches comprising at least one biodegradable polymer, an androgen receptor agonist and a bisphosphonate or pharmaceutically acceptable salt thereof for use in such methods.
    Type: Application
    Filed: November 8, 2019
    Publication date: March 5, 2020
    Applicant: OSTEO-PHARMA B.V.
    Inventor: Jan Albert GOSSEN
  • TOPICAL ANTIVIRAL FORMULATIONS
    Publication number: 20200069708
    Abstract: The present invention relates to formulations of antiviral compounds, in particular [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), suitable for topical application, and to their use in the reduction of or prevention of acquisition and transmission of herpes simplex virus.
    Type: Application
    Filed: January 18, 2019
    Publication date: March 5, 2020
    Inventors: Tomas Cihlar, Quarraisha Abdool Karim, Salim S. Abdool Karim, Ayesha Kharsany, James Francis Rooney
  • SYNTHETIC COMPOSITION FOR MICROBIOTA MODULATION
    Publication number: 20200069709
    Abstract: The invention relates to a method and composition for modulating the microbiota in the gastro-intestinal tracts of non-infant humans, particularly for increasing the abundance of Bifidobacterium longum and/or Bifidobacterium bifidum in the gut microbiota of non-infant humans.
    Type: Application
    Filed: March 1, 2018
    Publication date: March 5, 2020
    Inventors: Louise Kristine Vigsnæs, Bruce McConnell
  • COMPOSITIONS FOR TREATMENT OF HYPERGLYCEMIA IN DIABETES MELLITUS PATIENTS
    Publication number: 20200069710
    Abstract: Compositions comprising at least one steviol glycoside are provided for reducing increased blood sugar level (hyperglycemia) in Diabetes mellitus Type 1 and Type 2 patients.
    Type: Application
    Filed: April 18, 2018
    Publication date: March 5, 2020
    Inventor: Avetik MARKOSYAN
  • TREATING AND PREVENTING KIDNEY DAMAGE
    Publication number: 20200069711
    Abstract: Provided herein are methods and compositions related to treating and/or preventing kidney related diseases and disorders, treating and/or preventing acute kidney injury, and for improving kidney health in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.
    Type: Application
    Filed: April 23, 2018
    Publication date: March 5, 2020
    Inventors: Eric A. Marcotulli, Daniel A. Alminana, Leonard Pershing Guarente, Ryan Dellinger, Mark Morris
  • PHARMACEUTICAL COMPOUNDS AND USES THEREOF
    Publication number: 20200069712
    Abstract: Described herein are compounds pharmaceutically acceptable salts, isomers, mixture of isomers, crystalline forms, non-crystalline forms, hydrates, or solvates thereof, as well as methods using those compounds to, among other things, treat cancer.
    Type: Application
    Filed: August 30, 2019
    Publication date: March 5, 2020
    Inventors: DaQing Yang, Carston R. Wagner
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20200069713
    Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: June 19, 2019
    Publication date: March 5, 2020
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • AMINOGLYCOSIDE POTENTIATION FOR TREATMENT OF PULMONARY BACTERIAL INFECTION
    Publication number: 20200069714
    Abstract: The present invention provides methods and formulations for treating or preventing bacterial infection in the lungs of a subject, including for controlling P. aeruginosa infection and/or colonization in the lungs of a patient having a chronic lung condition, such as cystic fibrosis (CF), non-cystic fibrosis bronchiectasis (non-CFBE), chronic obstructive pulmonary disorder (COPD), among others. In some embodiments, the invention provides methods and formulations for treating mycobacterial infection.
    Type: Application
    Filed: December 8, 2017
    Publication date: March 5, 2020
    Inventors: Diane M. JOSEPH-MCCARTHY, Martina I. KOEVA
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
    Publication number: 20200069715
    Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 11, 2019
    Publication date: March 5, 2020
    Applicant: Lumena Pharmaceuticals LLC
    Inventors: Bronislava GEDULIN, Michael Grey, Niall O'Donnell
  • TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST
    Publication number: 20200069716
    Abstract: This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from sleep apnea, including obstructive sleep apnea syndrome (OSAS). Treatment is effected by administering a carbonic anhydrase inhibitor to the patient in combination with an aldosterone antagonist. Formulations containing a therapeutically effective amount of a carbonic anhydrase inhibitor and a therapeutically effective amount of an aldosterone antagonist are provided as well.
    Type: Application
    Filed: March 8, 2019
    Publication date: March 5, 2020
    Inventors: Charles H. BOWDEN, Craig PETERSON
  • NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20200069717
    Abstract: Disclosed herein, inter alia, are compounds, compositions, and methods of thereof in the sequencing a nucleic acid.
    Type: Application
    Filed: May 23, 2017
    Publication date: March 5, 2020
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Jingyue Ju, Xin Chen, Xiaoxu Li, Zengmin Li, Min-Kang Hsieh, Minchen Chien, Shundi Shi, Jianyi Ren, Cheng Guo, Shiv Kumar, James J. Russo, Chuanjuan Tao, Steffen Jockusch, Sergey Kalachikov
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH 5-IODO-2-PYRIMIDINONE-2'(prime)-DEOXYRIBOSE (IPdR)
    Publication number: 20200069718
    Abstract: Provided are methods of treating a human patient having cancer by administering IPdR to the patient in the form of an oral drug and administering radiation therapy (RT) to the patient. The method can also include administering a chemotherapeutic drug or biologic agent to the patient. Also provided are methods for optimizing IPdR sensitization for radiation therapy for a cancer patient having been administered IPdR.
    Type: Application
    Filed: May 15, 2019
    Publication date: March 5, 2020
    Applicant: EMEK, Inc.
    Inventor: Timothy J. Kinsella
  • Edible Energy Composition
    Publication number: 20200069719
    Abstract: An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, preservatives, and the like.
    Type: Application
    Filed: November 11, 2019
    Publication date: March 5, 2020
    Applicant: International IP Holdings LLC
    Inventor: Manoj Bhargava
  • MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes
    Publication number: 20200069720
    Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.
    Type: Application
    Filed: August 16, 2019
    Publication date: March 5, 2020
    Applicant: Julius-Maximilians-Universitat Wurzburg
    Inventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
  • STAUFEN1 AGENTS AND ASSOCIATED METHODS
    Publication number: 20200069721
    Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1 -regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 8, 2017
    Publication date: March 5, 2020
    Applicant: University of Utah Research Foundation
    Inventors: Stefan M. Pulst, Daniel R. Scoles, Sharan Paul